News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,223 Results
Type
Article (1072)
Company Profile (4)
Press Release (3147)
Multimedia
Podcasts (10)
Webinars (1)
Section
Business (1294)
Career Advice (58)
Deals (172)
Drug Delivery (6)
Drug Development (1176)
Employer Resources (11)
FDA (212)
Job Trends (461)
News (2599)
Policy (393)
Tag
Academia (28)
Accelerated approval (1)
Allergies (4)
Alliances (277)
Alzheimer's disease (6)
Antibody-drug conjugate (ADC) (2)
Approvals (213)
Artificial intelligence (1)
Autoimmune disease (1)
Automation (1)
Bankruptcy (2)
Best Places to Work (392)
Biosimilars (12)
Biotechnology (3)
Breast cancer (2)
Cancer (34)
Cardiovascular disease (3)
Career advice (46)
Career pathing (2)
CAR-T (2)
Cell therapy (12)
Clinical research (858)
Collaboration (12)
Compensation (1)
Complete response letters (3)
COVID-19 (185)
CRISPR (5)
C-suite (4)
Data (40)
Denatured (3)
Diabetes (2)
Diagnostics (32)
Digital health (1)
Diversity (3)
Diversity, equity & inclusion (3)
Drug discovery (2)
Drug pricing (5)
Duchenne muscular dystrophy (2)
Earnings (587)
Editorial (2)
Employer branding (7)
Employer resources (10)
Events (585)
Executive appointments (3)
FDA (239)
Funding (9)
Gene editing (9)
Gene therapy (18)
GLP-1 (31)
Government (116)
Grass and pollen (1)
Guidances (5)
Healthcare (123)
IgA nephropathy (1)
Immunology and inflammation (15)
Indications (1)
Infectious disease (187)
Influenza (1)
Interviews (11)
IPO (105)
IRA (1)
Job creations (89)
Job search strategy (45)
Labor market (4)
Layoffs (20)
Legal (53)
Liver cancer (2)
Lung cancer (5)
Lymphoma (4)
Management (2)
Manufacturing (12)
Medical device (20)
Medtech (20)
Mergers & acquisitions (72)
Metabolic disorders (21)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (12)
NextGen: Class of 2025 (58)
Non-profit (15)
Now hiring (17)
Obesity (18)
Opinion (4)
Pain (2)
Patents (5)
Peanut (1)
People (376)
Pharmaceutical (1)
Phase I (267)
Phase II (341)
Phase III (486)
Pipeline (38)
Policy (3)
Postmarket research (19)
Preclinical (72)
Rare diseases (8)
Real estate (32)
Recruiting (3)
Regulatory (302)
Reports (2)
Research institute (17)
Resumes & cover letters (6)
RSV (1)
Series A (5)
Series B (2)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (1)
Startups (13)
Tariffs (9)
The Weekly (7)
Vaccines (22)
Venture capitalists (3)
Weight loss (15)
Women's health (2)
Date
Today (5)
Last 7 days (14)
Last 30 days (51)
Last 365 days (399)
2025 (163)
2024 (387)
2023 (354)
2022 (557)
2021 (555)
2020 (535)
2019 (333)
2018 (237)
2017 (237)
2016 (167)
2015 (154)
2014 (105)
2013 (108)
2012 (81)
2011 (59)
2010 (45)
Location
Africa (23)
Asia (162)
Australia (58)
California (45)
Canada (4)
China (1)
Connecticut (5)
Delaware (2)
Europe (808)
Florida (1)
Idaho (1)
Illinois (5)
India (1)
Indiana (3)
Iowa (1)
Japan (1)
Maryland (1)
Massachusetts (47)
Michigan (1)
Minnesota (1)
Nebraska (1)
New Hampshire (2)
New Jersey (7)
New York (106)
North Carolina (8)
Northern California (30)
Ohio (2)
Oregon (1)
Pennsylvania (6)
Rhode Island (1)
South America (23)
Southern California (5)
Texas (1)
United States (221)
Virginia (2)
Washington D.C. (2)
Washington State (4)
Wisconsin (1)
4,223 Results for "regeneron".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
FDA Action Alert: Regeneron, Sanofi and Abeona
Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.
April 14, 2025
·
3 min read
·
Tristan Manalac
Manufacturing
Roche, Regeneron Pledge Multibillion Boosts to US Manufacturing as Trump’s Tariffs Loom
Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.
April 22, 2025
·
2 min read
·
Tristan Manalac
Legal
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea.
March 17, 2025
·
2 min read
·
Tristan Manalac
Legal
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that determine pricing and rebates for the drug.
February 7, 2025
·
2 min read
·
Tristan Manalac
Earnings
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall thanks in part to cancer therapy Libtayo and gave shareholders a cut of the profits for the first time in the company’s long history.
February 4, 2025
·
2 min read
·
Tristan Manalac
Drug development
Opthea, UNITY Fail to Unseat Regeneron’s Eylea in Vision Disorders
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s biosimilar from the U.S.
March 25, 2025
·
2 min read
·
Tristan Manalac
Cancer
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which exceeded the consensus by a modest 1% and are bogged down by the slow conversion of patients to the high-dose formulation.
January 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Regeneron Reports First Quarter 2025 Financial and Operating Results
April 30, 2025
·
29 min read
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Regeneron Announces Investor Conference Presentations - April 21, 2025
April 22, 2025
·
1 min read
1 of 423
Next
